muscimol has been researched along with Idiopathic Parkinson Disease in 16 studies
Muscimol: A neurotoxic isoxazole isolated from species of AMANITA. It is obtained by decarboxylation of IBOTENIC ACID. Muscimol is a potent agonist of GABA-A RECEPTORS and is used mainly as an experimental tool in animal and tissue studies.
muscimol : A member of the class of isoxazoles that is 1,2-oxazol-3(2H)-one substituted by an aminomethyl group at position 5. It has been isolated from mushrooms of the genus Amanita.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lactacystin is a selective UPS inhibitor recently used to destroy dopamine (DA) neurons in animal models of Parkinson's disease (PD)." | 1.42 | Decreased behavioral response to intranigrally administered GABAA agonist muscimol in the lactacystin model of Parkinson's disease may result from partial lesion of nigral non-dopamine neurons: comparison to the classical neurotoxin 6-OHDA. ( Czarnecka, A; Kamińska, K; Konieczny, J; Lenda, T; Nowak, P, 2015) |
| "When haloperidol was administered systemically in conjunction with microinfusion of muscimol into globus pallidus, an increase in nigral dopamine efflux was observed that was significantly greater than that which was produced singly by muscimol microinfusion into globus pallidus or by systemic haloperidol administration." | 1.32 | Relative involvement of globus pallidus and subthalamic nucleus in the regulation of somatodendritic dopamine release in substantia nigra is dopamine-dependent. ( Abercrombie, ED; Cobb, WS, 2003) |
| "In patients with Parkinson's disease, neurones in the STN display hyperactive firing rates and rhythmic discharge activity such as tremor-related oscillations (3-8 Hz) and synchronous high-frequency oscillations (15-30 Hz)." | 1.31 | Lidocaine and muscimol microinjections in subthalamic nucleus reverse Parkinsonian symptoms. ( Dostrovsky, JO; Hutchison, WD; Lang, AE; Levy, R; Lozano, AM; Pahapill, P; Romas, J; Saint-Cyr, J, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (18.75) | 18.7374 |
| 1990's | 3 (18.75) | 18.2507 |
| 2000's | 4 (25.00) | 29.6817 |
| 2010's | 6 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lima, JC | 1 |
| Oliveira, LM | 1 |
| Botelho, MT | 1 |
| Moreira, TS | 1 |
| Takakura, AC | 1 |
| Petri, D | 1 |
| Pum, M | 1 |
| Vesper, J | 1 |
| Huston, JP | 1 |
| Schnitzler, A | 1 |
| Bhutani, N | 1 |
| Sureshbabu, R | 1 |
| Farooqui, AA | 1 |
| Behari, M | 1 |
| Goyal, V | 1 |
| Murthy, A | 1 |
| Konieczny, J | 1 |
| Czarnecka, A | 1 |
| Kamińska, K | 1 |
| Lenda, T | 1 |
| Nowak, P | 1 |
| Brazhnik, E | 1 |
| McCoy, AJ | 1 |
| Novikov, N | 1 |
| Hatch, CE | 1 |
| Walters, JR | 1 |
| Pereira, EA | 1 |
| Nandi, D | 1 |
| Jenkinson, N | 1 |
| Stein, JF | 1 |
| Green, AL | 1 |
| Aziz, TZ | 1 |
| Cobb, WS | 1 |
| Abercrombie, ED | 1 |
| Takakusaki, K | 1 |
| Saitoh, K | 1 |
| Harada, H | 1 |
| Okumura, T | 1 |
| Sakamoto, T | 1 |
| Nishino, N | 2 |
| Hanada, S | 1 |
| Mita, T | 1 |
| Fujiwara, H | 2 |
| Tanaka, C | 2 |
| Noguchi-Kuno, SA | 2 |
| Ichikawa, K | 1 |
| Marsden, CD | 1 |
| Sheehy, MP | 1 |
| Penn, RD | 1 |
| Kroin, JS | 1 |
| Reinkensmeyer, A | 1 |
| Corcos, DM | 1 |
| Stasi, K | 1 |
| Mitsacos, A | 1 |
| Giompres, P | 1 |
| Kouvelas, ED | 1 |
| Triarhou, LC | 1 |
| Pahapill, PA | 1 |
| Levy, R | 2 |
| Dostrovsky, JO | 2 |
| Davis, KD | 1 |
| Rezai, AR | 1 |
| Tasker, RR | 1 |
| Lozano, AM | 2 |
| Lang, AE | 1 |
| Pahapill, P | 1 |
| Romas, J | 1 |
| Saint-Cyr, J | 1 |
| Hutchison, WD | 1 |
| Araki, T | 1 |
| Matsubara, M | 1 |
| Fujihara, K | 1 |
| Kato, H | 1 |
| Imai, Y | 1 |
| Itoyama, Y | 1 |
1 review available for muscimol and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Pedunculopontine stimulation from primate to patient.
Topics: Animals; Bicuculline; Biophysics; Convulsants; Deep Brain Stimulation; Disease Models, Animal; GABA- | 2011 |
1 trial available for muscimol and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
GABA and movement disorders.
Topics: Anticonvulsants; Baclofen; Clinical Trials as Topic; Double-Blind Method; Dyskinesia, Drug-Induced; | 1981 |
14 other studies available for muscimol and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
The involvement of the pathway connecting the substantia nigra, the periaqueductal gray matter and the retrotrapezoid nucleus in breathing control in a rat model of Parkinson's disease.
Topics: Animals; Chemoreceptor Cells; Disease Models, Animal; GABA Agonists; Glutamate Decarboxylase; Gray M | 2018 |
GABAA-receptor activation in the subthalamic nucleus compensates behavioral asymmetries in the hemiparkinsonian rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Amphetamine; Animals; Disease Models, Animal; Diz | 2013 |
Queuing of concurrent movement plans by basal ganglia.
Topics: Adult; Aged; Analysis of Variance; Animals; Basal Ganglia; Case-Control Studies; Caudate Nucleus; Fe | 2013 |
Decreased behavioral response to intranigrally administered GABAA agonist muscimol in the lactacystin model of Parkinson's disease may result from partial lesion of nigral non-dopamine neurons: comparison to the classical neurotoxin 6-OHDA.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcysteine; Animals; Cell Count; Corpus Striatum; Dopamine; Dose | 2015 |
Ventral Medial Thalamic Nucleus Promotes Synchronization of Increased High Beta Oscillatory Activity in the Basal Ganglia-Thalamocortical Network of the Hemiparkinsonian Rat.
Topics: Animals; Basal Ganglia; Beta Rhythm; Cerebral Cortex; Dopaminergic Neurons; Evoked Potentials; GABA | 2016 |
Relative involvement of globus pallidus and subthalamic nucleus in the regulation of somatodendritic dopamine release in substantia nigra is dopamine-dependent.
Topics: Animals; Dendrites; Dopamine; Dopamine Antagonists; Drug Synergism; Extracellular Space; GABA Antago | 2003 |
Evidence for a role of basal ganglia in the regulation of rapid eye movement sleep by electrical and chemical stimulation for the pedunculopontine tegmental nucleus and the substantia nigra pars reticulata in decerebrate cats.
Topics: Animals; Basal Ganglia; Bicuculline; Cats; Decerebrate State; Electric Stimulation; GABA Agonists; G | 2004 |
[Neurochemical pathology of GABAergic and cholinergic systems in Parkinson disease: an autopsy study].
Topics: Acetylcholine; Adult; Aged; Brain; Choline O-Acetyltransferase; Female; gamma-Aminobutyric Acid; Glu | 1984 |
Injection of GABA-agonist into globus pallidus in patient with Parkinson's disease.
Topics: Adult; GABA Agonists; Globus Pallidus; Humans; Injections, Intralesional; Male; Muscimol; Parkinson | 1998 |
Partial restoration of striatal GABAA receptor balance by functional mesencephalic dopaminergic grafts in mice with hereditary parkinsonism.
Topics: Animals; Autoradiography; Brain Tissue Transplantation; Corpus Striatum; Fetal Tissue Transplantatio | 1999 |
Tremor arrest with thalamic microinjections of muscimol in patients with essential tremor.
Topics: Aged; Electromyography; Female; Humans; Male; Microinjections; Muscimol; Parkinson Disease; Thalamus | 1999 |
Lidocaine and muscimol microinjections in subthalamic nucleus reverse Parkinsonian symptoms.
Topics: Aged; Anesthetics, Local; Dyskinesia, Drug-Induced; Female; GABA Agonists; Humans; Injections, Intra | 2001 |
Gamma-aminobutyric acidA and benzodiazepine receptor alterations in the rat brain after unilateral 6-hydroxydopamine lesions of the medial forebrain bundle.
Topics: Animals; Dopamine; Dopamine Uptake Inhibitors; Down-Regulation; Flunitrazepam; GABA Agonists; GABA M | 2002 |
GABAA receptor but not muscarinic receptor density was decreased in the brain of patients with Parkinson's disease.
Topics: Aged; Brain; Choline O-Acetyltransferase; Dopamine; Female; Glutamate Decarboxylase; Humans; Male; M | 1988 |